OREANDA-NEWS. September 16, 2015. Eli Lilly and Company (NYSE: LLY) will host a webcast on September 24 to discuss data from EMPA-REG OUTCOME®, a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 adults with type 2 diabetes at high risk for CV events. Detailed study results will be presented on Thursday, September 17 at the 51stEuropean Association for the Study of Diabetes (EASD) Annual Meeting in Stockholm, Sweden. JARDIANCE is part of the Boehringer Ingelheim and Lilly Diabetes Alliance.

The webcast on September 24 will begin at 10:00 a.m. Eastern Daylight Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at http://investor.lilly.com/events.cfm. A replay will be available for approximately one week.